Early preclinical and clinical data have shown that selinexor has broad activity against multiple hematologic malignancies and notable antimyeloma activity.
Researchers are promoting physician and patient awareness about the potential tie between depression and certain therapies.
Any images and personal stories that remind people about skin cancer, what to look for, even scars after surgery, really help save lives.
Even after an adverse event due to treatment with a checkpoint inhibitor, some patients may benefit from re-treatment with drugs from this class.
A growing body of evidence points to infiltrating myeloid-derived suppressor cells as key players in tumor progression and acquired treatment resistance.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immediate Instillation of Mitomycin C Post-TURBT May Benefit All Patients with Bladder Cancer
- IL-23 Drives Castration-Resistant Prostate Cancer
- FDA Grants Accelerated Approval to Nivolumab for Small Cell Lung Cancer
- Psychotherapy and Cancer
- Re-treatment With Checkpoint Inhibitors in Some Patients with NSCLC May Be Feasible
- Selinexor and Multiple Myeloma
- USPSTF Updates Its Recommendations for Cervical Cancer Screening
- Ibrutinib in Chronic Lymphocytic Leukemia Deemed Not Cost-Effective by ICER Standards
- Albumin-to-Fibrinogen Ratio May Predict Poor Outcomes in Chronic Lymphocytic Leukemia
- In Search of the Right Sequence for Venetoclax in CLL